Immunicom, Inc

Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients quality of life all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicoms cancer therapy has the potential to allow the bodys natural immune system to directly attack the cancer while enhancing the effects of other cancer treatments which may be used concurrently. At Immunicom we are reimagine how healing should be

Immunicom, inc operates in the Biotechnology industry.

Immunicom, inc's revenue is 11m - 100m

Immunicom, inc has 11 - 50 employees.